Actually, CD26 inhibitor, also known as DPP4 inhibitor or gliptin, are a class of oral hypoglycemic drugs that antagonize the enzyme DPP4 and are approved to treat diabetes mellitus type 2 (DM-II). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.